Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers

NCT ID: NCT04803708

Last Updated: 2022-10-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-22
• Study Completion Date: 2022-09-05

Brief Summary

This is a Phase I/IIa trial designed to evaluate topical bacteriophage therapy in patients with diabetic foot ulcers.

Detailed Description

The primary objective of this study is to evaluate the safety of a topical bacteriophage cocktail in the treatment of non infected and infected diabetic foot ulcers with Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumanni. Patients will also be evaluated for bacterial clearance and wound reduction.

Conditions

Diabetic Foot Ulcer; Pseudomonas Aeruginosa Infection; Staphylococcus Aureus Infection; Acinetobacter Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Part A- Cohort 1

8 eligible subjects with non-infected DFU will be enrolled (Cohort 1) and receive IP three times weekly (TIW) every other day for up to one week. Of these 8 enrolled subjects, 6 subjects will be randomized to TP-102 and 2 to placebo. Subjects will be followed-up for 7 days.

Group Type: EXPERIMENTAL

TP-102

Intervention Type: BIOLOGICAL

One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).

Part B- Cohort 2

18 subjects with a DFU with a grade 2 or 3 infection, as per PEDIS classification, and at least one bacterial strain susceptible to bacteriophage cocktail will be included in Cohort 2. Subjects will receive IP TIW, every other day, up to four weeks and will be randomized at a 2:1 randomization rate to either:

• TP-102 q.d 3x weekly up to four weeks (n=12)
• Placebo q.d. 3x weekly up to four weeks (n=6)

Subjects will be followed-up for 7 days.

Group Type: EXPERIMENTAL

TP-102

Intervention Type: BIOLOGICAL

One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).

Interventions

TP-102

One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Both cohorts:

• Type 1 or type 2 diabetes mellitus with glycated hemoglobin (HbA1c) ≤10, 5%
• Suitable physical and mental health as determined by the investigator based on medical history and general physical examination.
• Subjects must be medically stable based on clinical laboratory tests, medical history and vital signs. Clinical laboratory tests should be within normal values or not clinically significant, unless directly related to the condition of diabetes.
• Female subjects must fulfil one of the following criteria:

1. At least 1 year post-menopausal (amenorrhea >12 months prior to screening);

2. Surgically sterile (bilateral oophorectomy or hysterectomy);

3. If of childbearing potential, must agree to use a highly effective method of birth control from screening until 14 days after the last administration of IP.

• Female subjects of childbearing potential must have a negative pregnancy test at screening.
• Male subjects with a female partner of child-bearing potential or pregnant partner must agree to use a condom from screening until 14 days after the last IP application.
• ICF signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose of, and procedures required for the study and is willing to participate in the study.

Part A:

• Non-infected diabetic foot ulcer perfusion grade 1, depth grade 1 and infection grade 1 according to PEDIS classification.

Part B

• Infected diabetic foot ulcer meeting perfusion grade 1 or 2, depth grade 1 or 2 and infection 2 or 3,except if presence of abscess, fasciitis, osteomyelitis, and septic arthritis, according to PEDIS definition.
• Infected with at least one bacterial strain susceptible to bacteriophage cocktail assessed from culture.

Exclusion Criteria

Both cohorts:

• Study ulcer less than 2 cm away from other ulcers in case of multiple ulcers.
• History in the 5 previous years of any cancer requiring systemic chemotherapy or radiation.
• A condition that, in the opinion of the Investigator, could compromise the well being of the subject or course of the study, or prevent the subject from meeting or performing any study requirements.
• Immunocompromised subjects due to illness, organ transplant, or immune suppressive therapies (e.g. oral or parental corticosteroids, methotrexate, immune modulators) 3 months prior to screening. Ad hoc low dose inhaled corticosteroids or topical corticosteroids are not allowed from 2 weeks prior to randomization.
• Being pregnant or breastfeeding.
• Currently participating in another clinical trial or having participated in a previous clinical trial with receipt of an investigational product within 30 days of the first administration of IP or 5 half-lives, whichever is longer.
• Subjects that, in the opinion of the Investigator or their treating physician, are dependent of the following therapies for their ulcer treatment:

• Topical antimicrobial treatment (including isobetadine gel/dressing, silver nitrate dressing, topical antibiotic)
• Enzymatic, autolytic, maggot debridement
• Any active wound healing products (e.g., Dermagraft, Apligraf, Regranex, or Tegaderm hydrogel or others.)
• Physical or cleansing modalities, antiseptics, corticosteroids, growth factors, solutions other than sterile normal saline and ulcer treatments.

Part A:

• Clinically infected ulcers

Part B:

• Suspected or confirmed abscess, fasciitis, osteomyelitis or septic arthritis.
• Subjects meeting grade 3 or above PEDIS perfusion criteria
• Planed or anticipated surgery after screening

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

VectorB2B

INDUSTRY

Sponsor Role: collaborator

Technophage, SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ran Nir-Paz, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah Medical Organization

Ronen Ben Ami, MD

Role: PRINCIPAL_INVESTIGATOR

Tel-Aviv Sourasky Medical Center

Locations

Hadassah Medical Center, Ein Kerem

Jerusalem, , Israel

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Countries

Israel

References

Nir-Paz R, Onallah H, Dekel M, Gellman YN, Haze A, Ben-Ami R, Braunstein R, Hazan R, Dror D, Oster Y, Cherniak M, Attal F, Barbosa AR, Dordio H, Wagner A, Jones-Dias D, Neves J, Barreto M, Leandro C, Corte-Real S, Garcia M. Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers. Med. 2025 May 9;6(5):100565. doi: 10.1016/j.medj.2024.11.018. Epub 2024 Dec 30.

Reference Type: DERIVED

PMID: 39740667 (View on PubMed)

Other Identifiers

TP-102_101

Identifier Type: -

Identifier Source: org_study_id